These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 1846453)

  • 1. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
    Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
    [No Abstract]   [Full Text] [Related]  

  • 2. OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation.
    Knechtle SJ; Pirsch JD; Groshek M; Reed A; D'Alessandro AM; Kalayoglu M; Belzer FO; Sollinger HW
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1581-2. PubMed ID: 1846478
    [No Abstract]   [Full Text] [Related]  

  • 3. Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies.
    Henell KR; Bakke A; Kenny TA; Kimball JA; Barry JM; Norman DJ
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1070-1. PubMed ID: 1824886
    [No Abstract]   [Full Text] [Related]  

  • 4. Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation.
    Frenken LA; Hoitsma AJ; Tax WJ; Koene RA
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1072-3. PubMed ID: 1824887
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute cellular rejection during effective early prophylactic OKT3 monoclonal antibody treatment after renal transplantation.
    Haak HH; Weening JJ; Rischen-Vos J; Daha MR; van Es LA; van der Woude FJ
    Transplantation; 1989 Aug; 48(2):352-4. PubMed ID: 2526973
    [No Abstract]   [Full Text] [Related]  

  • 6. OKT3 resistant rejection in liver transplant patients.
    Sutherland F; Lazarovits A; Aboujaoude M; Grant D; Ghent C; Sommerauer J; Wall W
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1413-4. PubMed ID: 1824898
    [No Abstract]   [Full Text] [Related]  

  • 7. In situ antigenic modulation of human graft-infiltrating T cells is induced by OKT3 treatment.
    Caillat-Zucman S; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L
    Transplant Proc; 1990 Aug; 22(4):1782. PubMed ID: 2143860
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential immunosuppression: three years' experience in 240 cadaveric renal transplants.
    Light JA; Jonsson J; Khawand N; Ali A; Aquino A; Currier CB; Romolo J; Gonzalez J; Korb S
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1032-5. PubMed ID: 1899145
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute toxicity of anti-CD3 monoclonal antibody in mice: a model for OKT3 first dose reactions.
    Alegre M; Depierreux M; Florquin S; Najdovski T; Vandenabeele P; Abramowicz D; Leo O; Deschodt-Lanckman M; Goldman M
    Transplant Proc; 1990 Aug; 22(4):1920-1. PubMed ID: 2143864
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of a randomized monoclonal or polyclonal program of therapy on cytomegalovirus infection in kidney transplantation.
    Raffaele P; Pouteil-Noble C; Lefrancois N; Bosshard S; Betuel H; Aymard M; Dubernard JM; Touraine JL
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1361-2. PubMed ID: 1846465
    [No Abstract]   [Full Text] [Related]  

  • 12. Nashville antithymocyte serum: a safe and efficacious agent for prophylaxis after heart transplantation.
    Frist WH; Merrill WH; Eastburn TE; Stewart JR; Hammon JW; Fortune DS; Guy TS; Bender HW
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1160-1. PubMed ID: 1846455
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial.
    Waid TH; Lucas BA; Thompson JS; Munch LC; Brown S; Kryscio R; Prebeck R; VanHoy MA; Jezek D
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1062-5. PubMed ID: 1899152
    [No Abstract]   [Full Text] [Related]  

  • 14. Prolonged and repeated courses of OKT3 after liver transplantation.
    Colledan M; Gridelli B; Rossi G; Caccamo L; Gatti S; Bonara P; Fassati LR; Ferla G; Maggi U; Reggiani P
    Transplant Proc; 1990 Aug; 22(4):1769-71. PubMed ID: 2143859
    [No Abstract]   [Full Text] [Related]  

  • 15. Reactivity of patient antisera to OKT3 with a panel of CD3 monoclonal antibodies.
    Nashan B; Schwinzer R; Wonigeit K; Pichlmayr R
    Transplant Proc; 1989 Feb; 21(1 Pt 1):985-6. PubMed ID: 2523157
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of induction ALG (MALG) on the outcome of steroid-resistant rejection treated with OKT3 in renal transplant patients.
    Chiu A; Landsberg D; Cameron EC; Manson AD; Shackleton C
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1039-40. PubMed ID: 1899146
    [No Abstract]   [Full Text] [Related]  

  • 17. [Muromonab CD3].
    Akioka Y; Hattori M; Ito K
    Nihon Rinsho; 2005 May; 63 Suppl 5():747-50. PubMed ID: 15954439
    [No Abstract]   [Full Text] [Related]  

  • 18. An overview of the use of the monoclonal antibody OKT3 in renal transplantation.
    Norman DJ
    Transplant Proc; 1988 Dec; 20(6):1248-52. PubMed ID: 2974204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of interleukin 6 during OKT3 treatment in renal allograft recipients.
    Bloemena E; ten Berge IJ; Surachno J; Wilmink JM
    Transplantation; 1990 Aug; 50(2):330-1. PubMed ID: 2143327
    [No Abstract]   [Full Text] [Related]  

  • 20. Effective induction immunosuppression for cadaver renal transplantation at the St. Francis Regional Medical Center.
    Shield CF
    Clin Transpl; 1990; ():265-74. PubMed ID: 2129408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.